TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratificat
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.80
Evidence
0.88
Novelty
0.65
Feasibility
0.85
Impact
0.82
Druggability
0.90
Safety
0.72
Competition
0.68
Data
0.85
Reproducible
0.82
KG Connect
0.53
Score Breakdown
Dimension
TREM2-Deficient Microglia as D
Mechanistic
0.800
Evidence
0.880
Novelty
0.650
Feasibility
0.850
Impact
0.820
Druggability
0.900
Safety
0.720
Competition
0.680
Data
0.850
Reproducible
0.820
KG Connect
0.533
Evidence
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxic
No evidence citations yet
Debate Excerpts
TREM2-Deficient Microglia as Drivers of Amyloid Pl
4 rounds · quality: 0.49
Persona-Theorist
# Theoretical Analysis: TREM2-Deficient Microglia in Alzheimer's Disease
## Key Molecular Mechanisms
**TREM2-DAP12 Signaling Axis**: TREM2 is a surface receptor on microglia containing an immunogl...
Persona-Skeptic
## Critical Evaluation: TREM2 Hypothesis and Theoretical Analysis
### Core Strength Acknowledged
The genetic evidence is legitimately strong by AD standards—R47H represents one of the few variants...
Persona-Domain Expert
## Practical & Translational Assessment: TREM2 Agonism in AD
### Druggability: Favorable but CNS Delivery Is Key Challenge
TREM2 is a cell-surface receptor with a well-defined extracellular immuno...
Persona-Synthesizer
{"hypothesis_title":"TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease","synthesis_summary":"The TREM2 R47H variant represents one of the most robustly replicate...